Evidence map›Paper›PMID 37510273›Full record

ReviewGenes2023

Liquid Biopsy at the Frontier of Kidney Diseases: Application of Exosomes in Diagnostics and Therapeutics.

Ewud Agborbesong, John Bissler, Xiaogang Li

Open access · goldAbstract readReview
In one paragraph

Review in Genes, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. The role of extracellular vesicles in kidney disease progression.Kidney research and clinical practice · 2026
    Article
  6. Review
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Ewud AgborbesongDepartment of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA.
John BisslerDepartment of Pediatrics, University of Tennessee Health Science Center and Le Bonheur Children's Hospital, Memphis, TN 38105, USA.
Xiaogang LiDepartment of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Mayo Clinic · USSt. Jude Children's Research Hospital · USWinnMed · US

Funding

KIDNEY DISEASES RESEARCH TRAINING PROGRAMT32DK007013 · NIDDK · MAYO CLINIC ROCHESTER · PI LIESKE, JOHN C · 1986 to 2023
$3.7M
The crosstalk of DNA and lysine methyltransferases in ADPKD.R01DK126662 · NIDDK · MAYO CLINIC ROCHESTER · PI Xiaogang Li · 2020 to 2026
$3.0M
ADPKD: Understanding immunosuppression mechanisms and discovering treatmentR01DK129241 · NIDDK · MAYO CLINIC ROCHESTER · PI LI, XIAOGANG · 2021 to 2024
$1.8M
NIDDK NIH HHS R01 DK126662NIDDK NIH HHS R01 DK129241NIDDK NIH HHS T32 DK007013
6 · The paper itself

Abstract

In the era of precision medicine, liquid biopsy techniques, especially the use of urine analysis, represent a paradigm shift in the identification of biomarkers, with considerable implications for clinical practice in the field of nephrology. In kidney diseases, the use of this non-invasive tool to identify specific and sensitive biomarkers other than plasma creatinine and the glomerular filtration rate is becoming crucial for the diagnosis and assessment of a patient's condition. In recent years, studies have drawn attention to the importance of exosomes for diagnostic and therapeutic purposes in kidney diseases. Exosomes are nano-sized extracellular vesicles with a lipid bilayer structure, composed of a variety of biologically active substances. In the context of kidney diseases, studies have demonstrated that exosomes are valuable carriers of information and are delivery vectors, rendering them appealing candidates as biomarkers and drug delivery vehicles with beneficial therapeutic outcomes for kidney diseases. This review summarizes the applications of exosomes in kidney diseases, emphasizing the current biomarkers of renal diseases identified from urinary exosomes and the therapeutic applications of exosomes with reference to drug delivery and immunomodulation. Finally, we discuss the challenges encountered when using exosomes for therapeutic purposes and how these may affect its clinical applications.

Indexed as

ExosomesExtracellular VesiclesKidney DiseasesBiomarkersHumansLiquid BiopsyBiomarkersbiomarkerskidney diseasesliquid biopsytherapeuticsurinary exosomes

Identifiers

PMID37510273
PMCPMC10379367
OpenAlexW4382369670

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.